Further evidence of synergy comes from studies combining azacitidine with Nexturastat A, an HDAC6i, which revealed additive reductions in PD-L1 and DNMT1 expression across multiple ovarian cancer cell lines. Here, DNMT1 is linked to ovarian cancer.